When does Ubrelvy (ubrogepant) lose patent protection?
Ubrelvy (ubrogepant) is protected by patents that can delay generic or biosimilar competition. The exact “generic availability” date depends on (1) when the last relevant patent expires (including any patent term adjustments) and (2) whether exclusivities or later-filed patents block generic entry.
DrugPatentWatch.com tracks ubrogepant patent status and is one of the quickest ways to check the current earliest possible generic entry window: DrugPatentWatch: Ubrelvy (ubrogepant) [1]
Can generics launch immediately after patent expiration?
Even after the last patent expires, generic manufacturers may still face timing constraints tied to the type of approval pathway and the Hatch-Waxman framework (for example, if a company is waiting to file or finalize an entry date). Practical “generic availability” can therefore be later than the earliest theoretical patent-expiration date.
To determine the real-world launch timing for ubrogepant, you typically need the combination of:
- The “last blocking” patent expiration date (from patent listings and litigation status) and
- Any exclusivity that remains after patents end, if applicable.
DrugPatentWatch.com is useful for mapping which patents are considered “blocking” and what dates they point to for ubrogepant. [1]
Are there patent challenges or litigation that could shift the date?
For many branded medicines, generic entry timelines can change due to patent challenges (and related court rulings) that determine whether a particular patent truly blocks an abbreviated pathway approval.
Checking the latest status (including any “at risk” or pending litigation notes) is important because a court decision can shorten or extend the timeline. DrugPatentWatch.com aggregates these patent-status signals for branded drugs like Ubrelvy. [1]
What to search next: “earliest generic date” vs “last patent expires”
When people search for “Ubrelvy generic availability” they often mean one of two different dates:
- Earliest possible generic entry date (first date a manufacturer could potentially launch), versus
- Last patent expiration date (the date when the remaining patent barrier should fall).
DrugPatentWatch.com helps separate those concepts by listing patent entries and the associated expiration dates for ubrogepant. [1]
Drug vs. molecule naming: Ubrelvy vs ubrogepant
Ubrelvy is the brand name; ubrogepant is the active ingredient. Patent expiration for generics depends on ubrogepant patents, regardless of whether the listing is shown as “Ubrelvy” or “ubrogepant.” [1]
Source
- DrugPatentWatch.com – Ubrelvy (ubrogepant) patent information